Sarcomatoid Intrahepatic Cholangiocarcinoma After Immunotherapy:A Case Report and Review of the Literature  

作　　者：Zheng Zeng Yu Liu Jing Yu Qiang Xu Yong Wang Chang Zhao Ou Jiang 

机构地区：[1]Department of Abdominal Oncology,The Second People’s Hospital of Neijiang,Neijiang,Sichuan,China [2]Department of Pathology,The Second People’s Hospital of Neijiang,Neijiang,Sichuan,China

出　　处：《Journal of Clinical and Translational Hepatology》2022年第6期1240-1249,共10页临床与转化肝病杂志（英文版）

基　　金：from State Project for Essential Drug Research and Development of the People’s Republic of China(No.2018ZX09303014);the Health and Family Planning Commission of Sichuan Province(No.18PJ194).

摘　　要：Sarcomatoid carcinoma is a rare tumor that is composed of a mixture of malignant epithelial cells and mesenchymal cells.Many studies have reported that sarcomatoid carci-noma occurs in multiple organs including the liver.Sarco-matoid intrahepatic cholangiocarcinoma(S-iCCA)is an ex-tremely rare tumor that primarily occurs in the liver.This case occurred in a middle-aged man who was admitted to our hospital with abdominal pain.Enhanced computed to-mography of the abdomen showed a low-density mass in the upper right posterior lobe of the liver with enhancement in the periphery.Histological and immunohistochemical examination indicated that the tumor was malignant,with both cancer and sarcoma components,and was positive for cytokeratin and vimentin.The patient was diagnosed with S-iCCA.Metastases appeared in the liver and lung 4 months after surgery.Two cycles of chemotherapy were adminis-tered.Because of enlargement of the tumor,anti-angiogen-ic agents combined with immunotherapy were subsequently given to achieve disease control.To the best of our knowl-edge,this is the first reported case of a programmed cell death-1 inhibitor used in a S-iCCA patient.The purpose of this case report and literature review is to enhance clinician understanding of S-iCCA and to explore safe and effective treatment methods.

关 键 词：Sarcomatoid intrahepatic cholangiocarcinoma Sarcomatoid degen-eration PD-1 inhibitors Anti-angiogenic therapy 

分 类 号：R735.8[医药卫生—肿瘤]